India’s recent Covid-19 surge, which was initially driven by the Omicron sub-lineage JN.1.16 in April, has now shifted towards newer variants. Since May, the XFG variant—particularly its LF.7 and LP.81.2 sub-lineages—has gained prominence.
According to officials, genome sequencing of samples collected nationwide has identified four circulating sub-variants: LF.7, XFG, JN.1.16, and NB.1.8.1. Some of these strains were first detected in Singapore around five to six weeks ago and have since spread to India. “At present, these variants do not appear to cause more severe illness,” said Dr. Kumar, emphasizing that any decision regarding updates to the existing vaccines will be made after thorough evaluation by policymakers.
Currently, India has two Omicron-specific monovalent vaccines available: Corbivax by Biological E Limited and COVOVAX developed by the Serum Institute of India.
As part of the country’s ongoing genomic surveillance efforts, complete genome sequences of these new sub-variants have been submitted to both the Indian Biological Data Centre and the Global Initiative on Sharing All Influenza Data (GISAID).
Meanwhile, the number of active Covid-19 cases has seen a slight decline. As of June 18, India reported 6,483 active cases, down from 6,837 the previous day. Despite the emergence of new sub-variants, most patients continue to experience mild symptoms and are recovering at home. Since January 1, a total of 113 Covid-related deaths have been recorded, primarily among individuals with underlying health conditions.
Kerala continues to report the highest number of active cases, followed by Gujarat, Karnataka, and Delhi. As a precaution, the Union Health Ministry has instructed all states to maintain adequate preparedness by ensuring the availability of oxygen supplies, isolation beds, ventilators, and essential medicines.